Almirall SA ((GB:0O9B)), Almirall ((DE:E2Z)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Almirall S.A. has completed a Phase 3 clinical study titled A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis. The study aimed to assess the efficacy and safety of tirbanibulin ointment in treating actinic keratosis, a common skin condition.
The study tested the application of tirbanibulin, an experimental drug, compared to a vehicle ointment as a placebo. Participants applied the ointment daily for five days, with evaluations for efficacy and safety conducted at multiple intervals.
The study was designed as a randomized, double-blind, parallel-group trial with a primary treatment purpose. Both participants and investigators were blinded to the treatment allocation to ensure unbiased results.
Key dates for the study include its start on December 21, 2023, and the last update on July 27, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data availability.
The completion of this study may influence Almirall’s stock performance positively, as successful results could enhance the market potential of tirbanibulin. Investors may view this development favorably, especially in comparison to competitors in the dermatology sector.
The study is now completed, with further details available on the ClinicalTrials portal.